495 related articles for article (PubMed ID: 36822241)
1. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
3. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy and nanomedicine.
Sheng WY; Huang L
Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
6. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
7. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
8. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
9. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
10. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
11. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
[No Abstract] [Full Text] [Related]
12. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
Huang D; Wu T; Lan S; Liu C; Guo Z; Zhang W
Biomaterials; 2022 Oct; 289():121808. PubMed ID: 36137415
[TBL] [Abstract][Full Text] [Related]
13. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
15. Emerging nanomedicines for effective breast cancer immunotherapy.
Bahreyni A; Mohamud Y; Luo H
J Nanobiotechnology; 2020 Dec; 18(1):180. PubMed ID: 33298099
[TBL] [Abstract][Full Text] [Related]
16. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines.
Liu J; Liew SS; Wang J; Pu K
Adv Mater; 2022 Jan; 34(1):e2103790. PubMed ID: 34651344
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
18. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
Sheen MR; Fiering S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1524. PubMed ID: 29667346
[TBL] [Abstract][Full Text] [Related]
19. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
20. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
